Brand VerifiedChina

Sinocare Inc.

Sinocare

Sinocare is Asia's largest dedicated blood glucose monitoring manufacturer and a leading global player in diabetes care, founded in 2002 in Changsha, Hunan, China. With annual revenue of ¥4.659 billion, the company serves patients in 135+ countries with affordable glucose monitoring solutions. Sinocare is transitioning from traditional BGM to next-generation CGM technology.

Strengths: Massive volume-driven cost advantages with 48.74% gross margin; dominant position in price-sensitive emerging markets (135+ countries covered); ¥275M R&D investment in CGM technology development; fully automated production facilities in Changsha headquarters for extreme scale efficiency.
Weaknesses: Net profit collapsed 71.61% to ¥92.65M due to VBP price cuts and CGM investment; heavy R&D spend (5.89% of revenue) pressured near-term earnings; faces existential competitive pressure from Abbott and Dexcom in CGM segment.

Business Nature

Sinocare operates highly automated, vertically integrated manufacturing facilities in Changsha for blood glucose test strips and meters. The company combines massive scale production with a global distribution network spanning 135+ countries, focusing on affordable diabetes management solutions for price-sensitive markets.

Core Business Areas

Blood Glucose Monitoring – Core Business
• Traditional BGM blood glucose monitoring test strips and meters
• Developing CGM continuous glucose monitoring systems
• Diabetes management software and mobile applications
• Point-of-care HbA1c testing devices
• Hospital glucose monitoring systems
• Diabetes education and patient support services

Industry Rankings

10Top 10 Home Medical Devices Manufacturers & Suppliers

Mfr

10Top 10 Home Medical Devices Brands

Brand

Corporate Report

Sinocare is a China-based blood glucose monitoring specialist headquartered in Changsha, Hunan. Founded in 2002. Revenue ¥4.659 billion. 8,000+ employees. Products in 135+ countries.

Business Overview

Sinocare is Asia's largest dedicated BGM manufacturer, having built its business on making glucose testing affordable at scale. The company is now investing heavily in CGM technology to compete with Abbott and Dexcom in the next-generation diabetes monitoring market.

Key Strengths

Massive production scale with 48.74% gross margins through cost efficiency; 135+ country distribution network in emerging markets; ¥275M R&D investment in CGM development showing commitment to innovation; dominant position in price-sensitive global markets.

Challenges & Outlook

Net profit collapsed 71.61% to ¥92.65M due to VBP price cuts and CGM investment; faces existential competitive threat from Abbott Libre and Dexcom G7 in CGM; traditional BGM business is structurally declining; long and expensive path to profitability for CGM segment.

VerityRank Score

Based on our comprehensive evaluation across all four dimensions, Sinocare achieves a VerityRank Score of 83/100, reflecting its strong position in the global home medical devices industry.

VerityRank Score

83/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Changsha, Hunan, China

Founded

2002

Employees

8000+

Factories

4+ factories in China

Listing

SZSE: 300298

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website SZSE: 300298 , Data Sources & Methodology

Sinocare Official Website
Sinocare 2025 Annual Revenue
Sinocare 2025 Board Report
Sinocare - Wikipedia

Back to Rankings